Presentations and Posters
A Prospective Multicenter Randomized Phase II Neo-Adjuvant Study of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Docetaxel, Cyclophosphamide and Trastuzumab (TCH) Versus TCH Followed by FEC Versus TCH Alone, in Patients (pts) with Operable HER2 Positive Breast Cancer: JBCRG-10 Study
Norikazu Masuda, Nobuaki Sato, Kenji Higaki, Masahiro Kashiwaba, Nobuki Matsunami, Toshimi Takano, Jun Yamamura, Koji Kaneko, Masato Takahashi, Shinji Ohno, Tomomi Fujisawa, Shigeru Tsuyuki, Yasuo Miyoshi, Shoichiro Ohtani, Yutaka Yamamoto, Hiroko Bando, Toshinao Onoda, Hidetaka Kawabata, Satoshi Morita, Takayuki Ueno, Masakazu Toi
2012 SABCS Poster Session 1
A multicenter phase II trial of neoadjuvant letrozole plus low dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG07): the efficacy and its correlation with circulating endothelial cells
上野貴之、増田慎三、神垣俊二、森本卓、中村清吾、黒井克昌、岩田広治、大野真司、田中直、戸井雅和
2011 American Society of Clinical Oncology, Chicago (USA), Jun. 2011
A multicenter, randomized phase II study of neoadjuvant chemotherapy including trastuzumab with cyclophosphamide with docetaxel in patients with operable HER2-positive breast cancer (JBCRG-10 study)
Norikazu Masuda, Masakazu Toi, Takayuki Ueno, Kenjiro Aogi, Hiroji Iwata, Shinji Ohno, Katsumasa Kuroi, Nobuaoki Sato, Seigo Nakamura : Japan Breast Cancer Research Group (JBCRG)
2010 American Society of Clinical Oncology, Chicago (USA), Jun. 2010
The first report of the association between the recurrence score and risk of recurrence in Japanese population (JBCRG-TR03)
Masakazu Toi, Hiroji Iwata, Norikzau Masuda, Shinji Ohno, Seigo Nakamura, T Yamanaka, Takahiro Nakayama, Masahiro Kashiwaba, Shinji Kamigaki, Kenjiro Aogi, Takayuki Ueno, Katsumasa Kuroi : Japan Breast Cancer Research Group (JBCRG)
京都乳癌コンセンサス会議 2009 国際大会、京都、2009年4月
by Voluntary Organization JBCRG